Latest news and press releases about Neumora Therapeutics, Inc. Common Stock (NMRA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder.
Price
| Price | $0.77 |
| Market Cap | $143M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.57 |
| EV / EBITDA | -0.37 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -242.28% |
| Return on Invested Capital | -216.05% |
| Return on Assets | -169.86% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADCT · ALMS · AUTL · BCYC · FDMT · FULC · LXRX
Explore sector: Healthcare · Biotechnology
More sections of NMRA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks